Biohaven Ltd
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our U.S. headquarters is located in New Haven, Connecticut. Details of our leased and owned facilities, which include our U.S. headquarters and consist of office, lab, research, chemistry, and discovery facilities, are as follows:
| Location | Type | ApproximateSquare Feet | Lease Expiration |
|---|---|---|---|
| New Haven, Connecticut | Office Space | 42,000 | N/A |
| Cambridge, Massachusetts | Office & Lab Space | 27,000 | October, 2032 |
| Yardley, Pennsylvania | Office Space | 21,000 | September, 2027 |
| Pittsburgh, Pennsylvania | Office & Research Space | 20,000 | October, 2024 |
| New Haven, Connecticut | Office Space | 10,000 | N/A |
| New Haven, Connecticut | Chemistry & Discovery Facilities | 10,000 | December, 2024 |
| Dublin, Ireland | Office Space | 6,000 | April, 2027 |
We believe that our current facilities are suitable and adequate to meet our current needs and we believe that suitable additional or substitute space will be available as needed to accommodate any future expansions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.